Literature DB >> 15312144

Immune regulatory effect of pHSP65 DNA therapy in pulmonary tuberculosis: activation of CD8+ cells, interferon-gamma recovery and reduction of lung injury.

V L D Bonato1, E D C Gonçalves, E G Soares, R R Santos Júnior, A Sartori, A A M Coelho-Castelo, C L Silva.   

Abstract

A DNA vaccine based on the heat-shock protein 65 Mycobacterium leprae gene (pHSP65) presented a prophylactic and therapeutic effect in an experimental model of tuberculosis. In this paper, we addressed the question of which protective mechanisms are activated in Mycobacterium tuberculosis-infected mice after immune therapy with pHSP65. We evaluated activation of the cellular immune response in the lungs of infected mice 30 days after infection (initiation of immune therapy) and in those of uninfected mice. After 70 days (end of immune therapy), the immune responses of infected untreated mice, infected pHSP65-treated mice and infected pCDNA3-treated mice were also evaluated. Our results show that the most significant effect of pHSP65 was the stimulation of CD8+ lung cell activation, interferon-gamma recovery and reduction of lung injury. There was also partial restoration of the production of tumour necrosis factor-alpha. Treatment with pcDNA3 vector also induced an immune stimulatory effect. However, only infected pHSP65-treated mice were able to produce significant levels of interferon-gamma and to restrict the growth of bacilli.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15312144      PMCID: PMC1782550          DOI: 10.1111/j.1365-2567.2004.01931.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  31 in total

Review 1.  DNA vaccines: immunology, application, and optimization*.

Authors:  S Gurunathan; D M Klinman; R A Seder
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  The many faces of host responses to tuberculosis.

Authors:  H L Collins; S H Kaufmann
Journal:  Immunology       Date:  2001-05       Impact factor: 7.397

Review 3.  The TB epidemic from 1992 to 2002.

Authors:  Mario C Raviglione
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

4.  CD28 costimulation independence of target organ versus circulating memory antigen-specific CD4+ T cells.

Authors:  Andrew P Fontenot; Laia Gharavi; Sean R Bennett; Scott J Canavera; Lee S Newman; Brian L Kotzin
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

5.  Creating space: an antigen-independent, CpG-induced peripheral expansion of naive and memory T lymphocytes in a full T-cell compartment.

Authors:  Eduardo Davila; Maria G Velez; Carrie J Heppelmann; Esteban Celis
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

6.  Therapy of tuberculosis in mice by DNA vaccination.

Authors:  D B Lowrie; R E Tascon; V L Bonato; V M Lima; L H Faccioli; E Stavropoulos; M J Colston; R G Hewinson; K Moelling; C L Silva
Journal:  Nature       Date:  1999-07-15       Impact factor: 49.962

7.  Genetic aspects and microenvironment affect expression of CD18 and VLA-4 in experimental tuberculosis.

Authors:  V L D Bonato; E D C Goncalves; R R Santos; C L Silva
Journal:  Scand J Immunol       Date:  2002-08       Impact factor: 3.487

8.  Characterization of murine lung dendritic cells infected with Mycobacterium tuberculosis.

Authors:  M Gonzalez-Juarrero; I M Orme
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

Review 9.  Can we control tuberculosis in high HIV prevalence settings?

Authors:  Peter Godfrey-Faussett; Helen Ayles
Journal:  Tuberculosis (Edinb)       Date:  2003       Impact factor: 3.131

10.  Pulmonary necrosis resulting from DNA vaccination against tuberculosis.

Authors:  Jennifer L Taylor; Oliver C Turner; Randall J Basaraba; John T Belisle; Kris Huygen; Ian M Orme
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

View more
  27 in total

1.  Evaluation of the overall IFN-γ and IL-17 pro-inflammatory responses after DNA therapy of tuberculosis.

Authors:  Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Patricia R M Souza; Wendy M Rios; Luana S Soares; Rogério S Rosada; Izaíra T Brandão; Ana Paula Masson; Elaine M Floriano; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2013-01-16       Impact factor: 3.452

2.  Immunotherapy of tuberculosis with Mycobacterium leprae Hsp65 as a DNA vaccine triggers cross-reactive antibodies against mammalian Hsp60 but not pathological autoimmunity.

Authors:  Nayara T S Doimo; Carlos R Zárate-Bladés; Rodrigo F Rodrigues; Cristiane Tefé-Silva; Marcele N S Trotte; Patrícia R M Souza; Luana S Soares; Wendy M Rios; Elaine M Floriano; Izaira T Brandão; Ana P Masson; Verônica Coelho; Simone G Ramos; Celio L Silva
Journal:  Hum Vaccin Immunother       Date:  2014-03-07       Impact factor: 3.452

3.  Therapeutic DNA vaccine reduces schistosoma mansoni-induced tissue damage through cytokine balance and decreased migration of myofibroblasts.

Authors:  Fabiani Gai Frantz; Toshihiro Ito; Karen Angélica Cavassani; Cory M Hogaboam; Célio Lopes Silva; Steven L Kunkel; Lúcia H Faccioli
Journal:  Am J Pathol       Date:  2011-05-18       Impact factor: 4.307

4.  Evaluation of immuno-modulating effect of recombinant heat shock protein 40 of Brucella abortus in mice.

Authors:  Priyanka Minhas; B V Sunil Kumar; Ramneek Verma
Journal:  3 Biotech       Date:  2019-09-23       Impact factor: 2.406

5.  Protection conferred by heterologous vaccination against tuberculosis is dependent on the ratio of CD4(+) /CD4(+)  Foxp3(+) cells.

Authors:  Paola Fernanda Fedatto; Cássia Alves Sérgio; Marina Oliveira e Paula; Ana Flávia Gembre; Luís Henrique Franco; Pryscilla Fanini Wowk; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Walter Miguel Turato; Célio Lopes Silva; Denise Morais da Fonseca; Vânia Luiza Deperon Bonato
Journal:  Immunology       Date:  2012-11       Impact factor: 7.397

6.  A single dose of a DNA vaccine encoding apa coencapsulated with 6,6'-trehalose dimycolate in microspheres confers long-term protection against tuberculosis in Mycobacterium bovis BCG-primed mice.

Authors:  Dyego Carlétti; Denise Morais da Fonseca; Ana Flávia Gembre; Ana Paula Masson; Lívia Weijenborg Campos; Luciana C C Leite; Andréa Rodrigues Pires; Joseli Lannes-Vieira; Célio Lopes Silva; Vânia Luiza Deperon Bonato; Cynthia Horn
Journal:  Clin Vaccine Immunol       Date:  2013-06-05

7.  DNA vaccine containing the mycobacterial hsp65 gene prevented insulitis in MLD-STZ diabetes.

Authors:  Rubens R Santos; Alexandrina Sartori; Deison S Lima; Patrícia Rm Souza; Arlete Am Coelho-Castelo; Vânia Ld Bonato; Célio L Silva
Journal:  J Immune Based Ther Vaccines       Date:  2009-09-15

8.  Helminth coinfection does not affect therapeutic effect of a DNA vaccine in mice harboring tuberculosis.

Authors:  Fabiani G Frantz; Rogério S Rosada; Camila Peres-Buzalaf; Franciele R T Perusso; Vanderlei Rodrigues; Simone G Ramos; Steven L Kunkel; Célio L Silva; Lúcia H Faccioli
Journal:  PLoS Negl Trop Dis       Date:  2010-06-08

9.  Immune modulation induced by tuberculosis DNA vaccine protects non-obese diabetic mice from diabetes progression.

Authors:  R Rodrigues dos Santos Júnior; A Sartori; V L Deperon Bonato; A A M Coelho Castelo; C A Vilella; R L Zollner; C Lopes Silva
Journal:  Clin Exp Immunol       Date:  2007-06-22       Impact factor: 4.330

10.  Mycobacterium tuberculosis culture filtrate proteins plus CpG Oligodeoxynucleotides confer protection to Mycobacterium bovis BCG-primed mice by inhibiting interleukin-4 secretion.

Authors:  Denise Morais da Fonseca; Celio Lopes Silva; Pryscilla Fanini Wowk; Marina Oliveira E Paula; Simone Gusmão Ramos; Cynthia Horn; Gilles Marchal; Vânia Luiza Deperon Bonato
Journal:  Infect Immun       Date:  2009-09-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.